-
1
-
-
80052585091
-
-
National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health Accessed July 6, 2007
-
National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. U.S. Renal Data System: USRDS 2000 annual report, Bethesda, Maryland. http://www.usrds.org/atlas_2000.htm Accessed July 6, 2007
-
U.S. Renal Data System: USRDS 2000 annual report, Bethesda, Maryland
-
-
-
2
-
-
44949169590
-
-
U.S. Renal Data System, Division of Kidney, Urologic, and Hematological Disease, National Institute of Diabetes and Digestive Disease, National Institutes of Health, Bethesda, MD
-
U.S. Renal Data System. USRDS 2000 annual data report: atlas of endstage renal diseases in the United States (12th annual report) (2000), Division of Kidney, Urologic, and Hematological Disease, National Institute of Diabetes and Digestive Disease, National Institutes of Health, Bethesda, MD
-
(2000)
USRDS 2000 annual data report: atlas of endstage renal diseases in the United States (12th annual report)
-
-
-
3
-
-
0024370790
-
Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program
-
Hypertension Detection and Follow-Up Program Cooperative Group
-
Shulman N.B., Ford C.E., Hall W.D., et al., Hypertension Detection and Follow-Up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 13 (1989) I80-I93
-
(1989)
Hypertension
, vol.13
-
-
Shulman, N.B.1
Ford, C.E.2
Hall, W.D.3
-
4
-
-
33644854296
-
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
-
Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Ren Physiol 290 (2005) F262-F272
-
(2005)
Am J Physiol Ren Physiol
, vol.290
-
-
Vaziri, N.D.1
-
5
-
-
0242441465
-
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
-
Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 (2003) 1050-1065
-
(2003)
Hypertension
, vol.42
, pp. 1050-1065
-
-
Sarnak, M.J.1
Levey, A.S.2
Schoolwerth, A.C.3
-
6
-
-
0029931351
-
Outcome and risk factors of ischemic heart disease in chronic uremia
-
Parfrey P.S., Foley R.N., Harnett J.D., Kent G.M., Murray D., and Barre P.E. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 49 (1996) 1428-1434
-
(1996)
Kidney Int
, vol.49
, pp. 1428-1434
-
-
Parfrey, P.S.1
Foley, R.N.2
Harnett, J.D.3
Kent, G.M.4
Murray, D.5
Barre, P.E.6
-
7
-
-
0037394435
-
Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals
-
Fried L.F., Shlipak M.G., Crump C., et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41 (2003) 1364-1372
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 1364-1372
-
-
Fried, L.F.1
Shlipak, M.G.2
Crump, C.3
-
8
-
-
20544467918
-
Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999
-
Foley R.N., Murray A.M., Li S., et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16 (2005) 489-495
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 489-495
-
-
Foley, R.N.1
Murray, A.M.2
Li, S.3
-
9
-
-
16844376116
-
Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study
-
Muntner P., He J., Astor B.C., Folsom A.R., and Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 16 (2005) 529-538
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 529-538
-
-
Muntner, P.1
He, J.2
Astor, B.C.3
Folsom, A.R.4
Coresh, J.5
-
10
-
-
0034805996
-
Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia?
-
Nishizawa Y., Shoji T., Ishimura E., Inaba M., and Morii H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia?. Am J Kidney Dis 38 (2001) S4-S7
-
(2001)
Am J Kidney Dis
, vol.38
-
-
Nishizawa, Y.1
Shoji, T.2
Ishimura, E.3
Inaba, M.4
Morii, H.5
-
11
-
-
1642540483
-
Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition
-
Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291 (2004) 451-459
-
(2004)
JAMA
, vol.291
, pp. 451-459
-
-
Liu, Y.1
Coresh, J.2
Eustace, J.A.3
-
12
-
-
33144484038
-
Mechanisms of dyslipidemia of chronic renal failure
-
Vaziri N.D., and Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 10 (2006) 1-7
-
(2006)
Hemodial Int
, vol.10
, pp. 1-7
-
-
Vaziri, N.D.1
Moradi, H.2
-
13
-
-
0025755287
-
Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis
-
Attman P.O., and Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 57 (1991) 401-410
-
(1991)
Nephron
, vol.57
, pp. 401-410
-
-
Attman, P.O.1
Alaupovic, P.2
-
14
-
-
0034816578
-
Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease
-
Quaschning T., Krane V., Metzger T., and Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 38 (2001) S14-S19
-
(2001)
Am J Kidney Dis
, vol.38
-
-
Quaschning, T.1
Krane, V.2
Metzger, T.3
Wanner, C.4
-
15
-
-
0033016107
-
Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure
-
Vaziri N.D., Deng G., and Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 14 (1999) 1462-1466
-
(1999)
Nephrol Dial Transplant
, vol.14
, pp. 1462-1466
-
-
Vaziri, N.D.1
Deng, G.2
Liang, K.3
-
16
-
-
0017275662
-
Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man
-
Bagdade J., Casaretto A., and Albers J. Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med 87 (1976) 38-48
-
(1976)
J Lab Clin Med
, vol.87
, pp. 38-48
-
-
Bagdade, J.1
Casaretto, A.2
Albers, J.3
-
17
-
-
0036147221
-
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
-
Seliger S.L., Weiss N.S., Gillen D.L., et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61 (2002) 297-304
-
(2002)
Kidney Int
, vol.61
, pp. 297-304
-
-
Seliger, S.L.1
Weiss, N.S.2
Gillen, D.L.3
-
18
-
-
5644283332
-
Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients
-
Andreucci V.E., Fissell R.B., Bragg-Gresham J.L., et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 44 (2004) 61-67
-
(2004)
Am J Kidney Dis
, vol.44
, pp. 61-67
-
-
Andreucci, V.E.1
Fissell, R.B.2
Bragg-Gresham, J.L.3
-
19
-
-
22344458137
-
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
-
Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
-
(2005)
N Engl J Med
, vol.353
, pp. 238-248
-
-
Wanner, C.1
Krane, V.2
Marz, W.3
-
20
-
-
34250640802
-
N-3 Fatty Acids as Secondary Prevention Against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: a randomized, placebo-controlled intervention trial
-
Svensson M., Schmidt E.B., Jorgensen K.A., and Christensen J.H. N-3 Fatty Acids as Secondary Prevention Against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 1 (2006) 780-786
-
(2006)
Clin J Am Soc Nephrol
, vol.1
, pp. 780-786
-
-
Svensson, M.1
Schmidt, E.B.2
Jorgensen, K.A.3
Christensen, J.H.4
-
21
-
-
0037407559
-
Why do we need a statin trial in hemodialysis patients?
-
Fellstrom B.C., Holdaas H., and Jardine A.G. Why do we need a statin trial in hemodialysis patients?. Kidney Int 63 Suppl (2003) S204-S206
-
(2003)
Kidney Int
, vol.63
, Issue.SUPPL
-
-
Fellstrom, B.C.1
Holdaas, H.2
Jardine, A.G.3
-
22
-
-
0037407617
-
Study of Heart and Renal Protection (SHARP)
-
Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 63 Suppl (2003) S207-S210
-
(2003)
Kidney Int
, vol.63
, Issue.SUPPL
-
-
Baigent, C.1
Landry, M.2
-
23
-
-
0037031061
-
MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: a randomised placebo-controlled trial
-
Heart Protection Study Collaborative Group
-
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
-
(2002)
Lancet
, vol.360
, pp. 7-22
-
-
-
24
-
-
0037458229
-
Cholesterol and Recurrent Events Trial I. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency
-
Tonelli M., Moye L., Sacks F.M., Kiberd B., and Curhan G. Cholesterol and Recurrent Events Trial I. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 (2003) 98-104
-
(2003)
Ann Intern Med
, vol.138
, pp. 98-104
-
-
Tonelli, M.1
Moye, L.2
Sacks, F.M.3
Kiberd, B.4
Curhan, G.5
-
25
-
-
8144224441
-
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria
-
Asselbergs F.W., Diercks G.F., Hillege H.L., et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 (2004) 2809-2816
-
(2004)
Circulation
, vol.110
, pp. 2809-2816
-
-
Asselbergs, F.W.1
Diercks, G.F.2
Hillege, H.L.3
-
26
-
-
10744229858
-
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
-
Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
-
(2003)
Lancet
, vol.361
, pp. 2024-2031
-
-
Holdaas, H.1
Fellstrom, B.2
Jardine, A.G.3
-
27
-
-
2942592399
-
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study
-
Jardine A.G., Holdaas H., Fellstrom B., et al. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study. Am J Transplant 4 (2004) 988-995
-
(2004)
Am J Transplant
, vol.4
, pp. 988-995
-
-
Jardine, A.G.1
Holdaas, H.2
Fellstrom, B.3
-
28
-
-
4344560351
-
Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficienc
-
Veterans' Affairs High-Density Lipoprotein Intervention Trial Investigators
-
Tonelli M., Collins D., Robins S., Bloomfield H., Curhan G.C., and Veterans' Affairs High-Density Lipoprotein Intervention Trial Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficienc. Kidney Int 66 (2004) 1123-1130
-
(2004)
Kidney Int
, vol.66
, pp. 1123-1130
-
-
Tonelli, M.1
Collins, D.2
Robins, S.3
Bloomfield, H.4
Curhan, G.C.5
-
29
-
-
0037379751
-
K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease
-
K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am J Kidney Dis 41 Suppl 3 (2003) S1-S237
-
(2003)
Am J Kidney Dis
, vol.41
, Issue.SUPPL. 3
-
-
-
30
-
-
20044372379
-
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation
-
Corsini A., and Holdass H. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Ren Fail 27 (2005) 259-273
-
(2005)
Ren Fail
, vol.27
, pp. 259-273
-
-
Corsini, A.1
Holdass, H.2
-
31
-
-
0028200059
-
Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase
-
Blum C.B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Am J Cardiol 73 (1994) 3D-11D
-
(1994)
Am J Cardiol
, vol.73
-
-
Blum, C.B.1
-
32
-
-
0025252565
-
Proteinuria as complication of simvastatin treatment
-
Deslypere J.P., Delanghe J., and Vermeulen A. Proteinuria as complication of simvastatin treatment. Lancet 336 (1990) 1453
-
(1990)
Lancet
, vol.336
, pp. 1453
-
-
Deslypere, J.P.1
Delanghe, J.2
Vermeulen, A.3
-
33
-
-
22144442778
-
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease
-
Tonelli M., Isles C., Craven T., et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112 (2005) 171-178
-
(2005)
Circulation
, vol.112
, pp. 171-178
-
-
Tonelli, M.1
Isles, C.2
Craven, T.3
-
35
-
-
32844458440
-
Effects of statins on renal function
-
Agarwal R. Effects of statins on renal function. Am J Cardiol 97 (2006) 748-755
-
(2006)
Am J Cardiol
, vol.97
, pp. 748-755
-
-
Agarwal, R.1
-
36
-
-
0031801034
-
In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation
-
Abbate M., Zoja C., Corna D., Capitanio M., Bertani T., and Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9 (1998) 1213-1224
-
(1998)
J Am Soc Nephrol
, vol.9
, pp. 1213-1224
-
-
Abbate, M.1
Zoja, C.2
Corna, D.3
Capitanio, M.4
Bertani, T.5
Remuzzi, G.6
-
37
-
-
0023508823
-
The effect of renal function on the pharmacokinetics of gemfibrozil
-
Evans J.R., Forland S.C., and Cutler R.E. The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol 27 (1987) 994-1000
-
(1987)
J Clin Pharmacol
, vol.27
, pp. 994-1000
-
-
Evans, J.R.1
Forland, S.C.2
Cutler, R.E.3
-
38
-
-
0023634450
-
Pharmacology of fenofibrate
-
Chapman M.J. Pharmacology of fenofibrate. Am J Med 83 (1987) 21-25
-
(1987)
Am J Med
, vol.83
, pp. 21-25
-
-
Chapman, M.J.1
-
40
-
-
0036843479
-
Effects of fibrates on metabolism of statins in human hepatocytes
-
Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., and Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
-
(2002)
Drug Metab Dispos
, vol.30
, pp. 1280-1287
-
-
Prueksaritanont, T.1
Tang, C.2
Qiu, Y.3
Mu, L.4
Subramanian, R.5
Lin, J.H.6
-
41
-
-
28044452217
-
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
-
[see comment]
-
Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. [see comment]. Lancet 366 (2005) 1849-1861
-
(2005)
Lancet
, vol.366
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
-
42
-
-
0032617597
-
Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency
-
Hottelart C., el Esper N., Achard J.M., Pruna A., and Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 20 (1999) 41-44
-
(1999)
Nephrologie
, vol.20
, pp. 41-44
-
-
Hottelart, C.1
el Esper, N.2
Achard, J.M.3
Pruna, A.4
Fournier, A.5
-
43
-
-
0025348840
-
Gemfibrozil absorption and elimination in kidney and liver disease
-
Knauf H., Kolle E.U., and Mutschler E. Gemfibrozil absorption and elimination in kidney and liver disease. Klin Wochenschr 68 (1990) 692-698
-
(1990)
Klin Wochenschr
, vol.68
, pp. 692-698
-
-
Knauf, H.1
Kolle, E.U.2
Mutschler, E.3
-
44
-
-
2342487350
-
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels
-
Dierkes J., Westphal S., and Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 3 (2004) 101-111
-
(2004)
Expert Opin Drug Saf
, vol.3
, pp. 101-111
-
-
Dierkes, J.1
Westphal, S.2
Luley, C.3
-
45
-
-
0016630250
-
Clofibrate and niacin in coronary heart disease
-
Anonymous
-
Anonymous. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
-
(1975)
JAMA
, vol.231
, pp. 360-381
-
-
-
46
-
-
0035822253
-
Effects of fenofibrate and gemfibrozil on plasma homocysteine
-
Westphal S., Dierkes J., and Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358 (2001) 39-40
-
(2001)
Lancet
, vol.358
, pp. 39-40
-
-
Westphal, S.1
Dierkes, J.2
Luley, C.3
-
47
-
-
33645800801
-
Fibrates in combination with statins in the management of dyslipidemia
-
Jacobson T.A., and Zimmerman F.H. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens 8 (2006) 35-41
-
(2006)
J Clin Hypertens
, vol.8
, pp. 35-41
-
-
Jacobson, T.A.1
Zimmerman, F.H.2
-
48
-
-
33947124605
-
Safety considerations with gastrointestinally active lipid-lowering drugs
-
Jacobson T.A., Armani A., McKenney J.M., and Guyton J.R. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 99 (2007) 47C-55C
-
(2007)
Am J Cardiol
, vol.99
-
-
Jacobson, T.A.1
Armani, A.2
McKenney, J.M.3
Guyton, J.R.4
-
49
-
-
22244440549
-
Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients
-
Yamada K., Fujimoto S., Tokura T., et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 27 (2005) 361-365
-
(2005)
Ren Fail
, vol.27
, pp. 361-365
-
-
Yamada, K.1
Fujimoto, S.2
Tokura, T.3
-
50
-
-
32844473141
-
The second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD
-
Landray M., Baigent C., Leaper C., et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47 (2006) 385-395
-
(2006)
Am J Kidney Dis
, vol.47
, pp. 385-395
-
-
Landray, M.1
Baigent, C.2
Leaper, C.3
-
51
-
-
0037126526
-
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
-
National Cholesterol Education Program Expert Panel on Detection
-
National Cholesterol Education Program Expert Panel on Detection. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
-
(2002)
Circulation
, vol.106
, pp. 3143-3421
-
-
-
52
-
-
20444399162
-
Nonfasting nonhigh-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients
-
Desmeules S., Arcand-Bosse J.F., Bergeron J., Douville P., and Agharazii M. Nonfasting nonhigh-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis 45 (2005) 1067-1072
-
(2005)
Am J Kidney Dis
, vol.45
, pp. 1067-1072
-
-
Desmeules, S.1
Arcand-Bosse, J.F.2
Bergeron, J.3
Douville, P.4
Agharazii, M.5
-
53
-
-
33947113384
-
Safety considerations with omega-3 fatty acid therapy
-
Bays H.E. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 99 (2007) 35C-43C
-
(2007)
Am J Cardiol
, vol.99
-
-
Bays, H.E.1
-
54
-
-
33747129220
-
Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids
-
Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 98 (2006) 71i-76i
-
(2006)
Am J Cardiol
, vol.98
-
-
Bays, H.1
|